|
Formosa Laboratories, Inc. is a Contract Development and Manufacturing Organization (CDMO) established in 1995 that provides API process development, impurity identification, and synthesis services. The company entered GMP API manufacturing in 2000 and offers facilities for Active Pharmaceutical Ingredients (APIs), High Potency APIs (HPAPIs), Antibody-Drug Conjugates (ADCs), and injectables. Its service portfolio includes custom synthesis, bioconjugation, injectable manufacturing, custom fermentation, and peptide synthesis, supporting clients from pilot plant to commercial scale. Formosa Laboratories manufactures generic medicines, including Eribulin Injection, which has received approval from the U.S. Food and Drug Administration and marketing approval in Europe. The company partners with Jiksak Bioengineering Inc. to develop ADC innovations for neurological diseases and collaborates with a U.S. pharmaceutical company for the supply of breast cancer chemotherapy injections. Its manufacturing processes comply with cGMP regulations and are inspected by the TFDA, FDA, EDQM, and PMDA. Summarised from the company's own disclosures, fiscal year ended Oct 2026 |
Industry Drug Manufacturers - Specialty & Generic | Homepage formosalab.com |
| Sector Healthcare | IR page formosalab.com/investor | |
|
Tags
contract development and manufacturing, active pharmaceutical ingredients, high potency apis, antibody-drug conjugates, injectable manufacturing, peptide synthesis, custom fermentation, generic medicines, oncology, neurological diseases, Eribulin Injection, Jiksak Bioengineering Inc.
|
Press page formosalab.com/news |
Metrics
| Valuation | |
|---|---|
| Market cap | NT$ 4.937B |
| Market cap (USD) | $ 149.832M |
| P/E | 12.40 |
| PEG | 4.92 |
| P/BV | 0.64 |
| P/S | 1.02 |
| P/OCF | 6.80 |
| P/FCF | — |
| Dividend yield | — |
| Turnover / mcap | — |
| Returns | |
|---|---|
| ROE | 5.7% |
| ROI | 5.7% |
| ROIC | 8.2% |
| Profit margin | 9.1% |
| Growth | |
|---|---|
| Revenue growing | Yes |
| Profits growing | Yes |
| Revenue up 3y | Yes |
| Revenue up 5y | Yes |
| Earnings growth 3y (net profit CAGR) | 2.5% |
| Quality | |
|---|---|
| Profitable | Yes |
| Margin expanding | Yes |
| Buying back stock | No |
| Diluting (TTM) | No |
| Debt/Equity | — |
| Podcast bulls (TTM) | Sign up |
| Podcast bears (TTM) | Sign up |
| Podcast sentiment (TTM) | Sign up |
| Podcast sentiment % (TTM) | Sign up |
| News sentiment (TTM) | 3 |
| Quality score | 56.3% |
| Insiders | |
|---|---|
| Buys, 1w | Sign up |
| Buys, 1m | Sign up |
| Buys, 1y | Sign up |
| Sells, 1w | Sign up |
| Sells, 1m | Sign up |
| Sells, 1y | Sign up |
Sign up to see this company's insider trades
| Figure | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 | FY 2014 | FY 2013 | FY 2012 | FY 2011 | FY 2010 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 4.851B | 4.731B | 4.36B | 3.766B | 3.142B | 3.075B | 2.76B | 2.688B | 2.539B | 3.189B | 2.597B | 2.496B | 2.474B | 2.524B | 2.626B | 2.506B |
| Net profit | 441.107M | 157.268M | 126.243M | 409.359M | 1.249B | 400.034M | 11.631M | 176.821M | 238.645M | 483.441M | 282.392M | 262.495M | -69.401M | 5.003M | 231.067M | 246.621M |
| Figure | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 | FY 2014 | FY 2013 | FY 2012 | FY 2011 | FY 2010 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Share price | 59.3 | 68.8 | 102 | 73.5 | 60.5 | 46.95 | — | — | — | — | — | — | — | — | — | — |
| Price performance 12m | -0.14 | -0.33 | 0.39 | 0.21 | 0.29 | — | — | — | — | — | — | — | — | — | — | — |
Sign up to see institutional holdings
Sign UpPodcast Mentions
Sign up to see podcast mentions and sentiment
Sign UpMaterial information published on MOPS, newest first, subjects as filed in Chinese, guarantee and loan balance notices and routine equipment purchases included. The link opens the company's material information on MOPS. Press releases from the company's own website, newest first.
Prompts
Click prompts to add them under the company line, click again to take one out, then copy the result into your AI chat. Shared by Asian Century Stocks and Uncovered Thai Stocks. Thank you.
ETFs Holding Formosa Laboratories, Inc.
Exchange-traded funds whose newest published daily portfolio holds one of the company's listings, largest weight first.
| ETF | Weight in ETF | Shares | Market value | As of |
|---|---|---|---|---|
| AVEE | 0.01% | 12,000 | $ 16.414K | Nov 16, 2026 |
| DEXC | 0.00% | 8,000 | $ 11.101K | Nov 12, 2026 |
| DFEV | 0.00% | 59,000 | $ 81.871K | Nov 12, 2026 |
| DFEM | 0.00% | 167,000 | $ 231.737K | Nov 12, 2026 |
| DFAE | 0.00% | 115,000 | $ 159.579K | Nov 12, 2026 |
| DFAX | 0.00% | 74,108 | $ 102.836K | Nov 12, 2026 |
| AVEM | 0.00% | 160,000 | $ 218.852K | Nov 16, 2026 |
| AVES | 0.00% | 22,000 | $ 30.092K | Nov 16, 2026 |
| AVSE | 0.00% | 2,000 | $ 2,735.65 | Nov 16, 2026 |
| AVXC | 0.00% | 6,000 | $ 8,206.96 | Nov 16, 2026 |
